Table 4.
Median IgG4 responses (MFI) to Bm14 and Bm33 from treatment groups in 95 children at time points A, B, and C, Haiti*
| Observation (antigen and isotype responses) | Treatment group (no.) | |||
|---|---|---|---|---|
| Placebo (22) | ALB (24) | DEC (24) | DEC/ALB (25) | |
| Pretreatment (time point A) | ||||
| Bm14/IgG4 | 2,095 | 7,153 | 457 | 708 |
| Bm33/IgG4 | 163 | 117 | 122 | 133 |
| Three months post-treatment (time point B) | ||||
| Bm14/IgG4 | 1,449 | 764 | 79† | 163† |
| Bm33/IgG4 | 164 | 107 | 98† | 79† |
| Six months post-treatment (time point C) | ||||
| Bm14/IgG4 | 721‡ | 703‡ | 73† | 77† |
| Bm33/IgG4 | 121 | 115‡ | 76† | 73† |
*
MFI = median fluorescence intensity; bg = background; ALB = albendazole; DEC = diethylcarbamazine.
†
Median values (MFI, IgG4 responses) significantly lower (P < 0.001) compared with time point A in the same treatment group (by Tukey test).
‡
Median values (MFI, IgG4 responses) significantly lower (P < 0.022) compared with time point A in the same treatment group (by Tukey test).